Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04191330 · ClinicalTrials.gov registry record · NA
Artificial Intelligence Mobile Health Trial Of A Digital Platform To Optimize GDMT Using Wearable Sensors
A NA study of Heart Failure, sponsored by Biofourmis.
- Active
- Registry status
- NA
- Development phase
- 122
- Enrollment target
- 14
- Study locations
NCT04191330: Active NA study of Heart Failure, sponsored by Biofourmis.
NCT04191330 is a NA study of Heart Failure that is active but no longer recruiting, run by Biofourmis. The registered enrollment target is 122 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (94% lower). The trial reports 14 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04191330, a NA study of Heart Failure, is active but no longer recruiting, sponsored by Biofourmis.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 122 participants
- Enrollment target
- 14
- Study locations
Study Summary
The goal of this real-world, multi-center, randomized, outpatient study is to assess the effectiveness of the Biofourmis cloud based BiovitalsHF platform to recommend optimal titration of Guideline-Directed Medical Therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) subjects.
Conditions Studied
Interventions
- DEVICE BiovitalsHF
Study Locations (14)
Arkansas
- Cardiology and Medicine Clinic - Little Rock
District of Columbia
- Medstar Washington Hospital Center - Washington D.C.
Georgia
- Piedmont Athens Regional Medical Center - Athens
Kentucky
- Baptist Health Louisville Heart Failure Clinic - Louisville
Louisiana
- Cambridge Medical Trials - Alexandria
Maryland
- Medstar Union Memorial Hospital - Baltimore
Michigan
- St Joseph Mercy - Ypsilanti
Mississippi
- Jackson Heart - Jackson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2020-01-27 |
| Est. Completion | 2024-08-31 |
| Phase | NA |
What the registry record for NCT04191330 still lists
NCT04191330 is an interventional study that assigns participants to a tested intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which BiovitalsHF is the first listed.
NCT04191330 lists 14 locations in 14 states (Arkansas, District of Columbia, Georgia).
Frequently Asked Questions
What is clinical trial NCT04191330 about?
NCT04191330 is a clinical study titled "Artificial Intelligence Mobile Health Trial Of A Digital Platform To Optimize GDMT Using Wearable Sensors". The goal of this real-world, multi-center, randomized, outpatient study is to assess the effectiveness of the Biofourmis cloud based BiovitalsHF platform to recommend optimal titration of Guideline-Directed Medical Therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) subjects.
What is the current status of trial NCT04191330?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 122 participants. The study started on 2020-01-27. Estimated completion is 2024-08-31.
What conditions does trial NCT04191330 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT04191330?
The interventions under investigation include: BiovitalsHF (DEVICE).
Who is sponsoring clinical trial NCT04191330?
This trial is sponsored by Biofourmis, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04191330 being conducted?
This trial has 14 study locations across Arkansas, District of Columbia, Georgia, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04191330's enrollment target sits among peer trials
122 201st of 397 higher than 197 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
RECRUITING · NA
-
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
RECRUITING · NA
-
Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI